GlassScriptPhysician profile
Josemaria Paterno
NPI 1679885693
$21,254.17
in general payments reported to CMS, 2019-2025
27 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,564 · 2020: $2,109 · 2021: $4,745 · 2022: $3,600 · 2023: $2,886 · 2024: $4,298 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,235.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,515.14 | 2019-2025 | Proclaim, Octrode, Swift-Lock |
| Boston Scientific Corporation | $1,512.59 | 2019-2023 | |
| Medtronic, INC. | $702.33 | 2021-2025 | Synchromedii, Primeadvanced Surescan, Intellis Adaptivestim |
| Medtronic USA, INC. | $183.15 | 2020 | |
| Biodelivery Sciences International, INC. | $179.91 | 2019 | |
| Nalu Medical, INC. | $122.35 | 2024 | Nalu Neurostimulation System |
| Globus Medical, INC. | $115.78 | 2025 | Senza |
| Pfizer INC. | $115.02 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $106.77 | 2019-2024 | Belbuca |
| Amgen INC. | $75.01 | 2021-2022 | |
| Protega Pharmaceutials INC | $71.99 | 2025 | Roxybond |
| Spr Therapeutics, INC | $68.00 | 2023 | Sprint Pns System |
| Grt US Holding, INC. | $58.82 | 2021-2022 | |
| Radius Health, INC. | $51.66 | 2019 | |
| Daiichi Sankyo INC. | $41.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $41.03 | 2022 | |
| Abbvie INC. | $35.60 | 2022-2024 | |
| Forte Bio-Pharma LLC | $35.36 | 2019-2021 | |
| Ibsa Pharma INC. | $34.69 | 2022-2023 | Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $30.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $29.15 | 2019 | |
| Tersera Therapeutics LLC | $26.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.88 | 2022 | |
| Celgene Corporation | $23.49 | 2019 | |
| Horizon Therapeutics Plc | $17.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josemaria Paterno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.